---
schema_version: "secwatch.filing_event.v1"
accession: "0001828185-24-000073"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:11:09.782263+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Barinthus Bio Q2 2024 net loss $16.9M; prioritizes HBV and celiac programs; CMO hired

## Summary
- Net loss of $16.9M ($0.43 per share) compared to $15.5M ($0.40) in Q1 2024.
- Cash $117.8M at June 30, 2024, down from $130.0M at March 31, 2024; runway into Q2 2026.
- Pipeline prioritized: VTP-300 (HBV) and VTP-1000 (celiac disease); workforce reduction announced.
- Dr. Leon Hooftman appointed Chief Medical Officer effective June 3, 2024.
- Upcoming milestones: VTP-1000 Phase 1 first patient dosing in Q3 2024; HBV data updates in Q4 2024.

## SEC filing metadata
- accession: 0001828185-24-000073
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000182818524000073/0001828185-24-000073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000182818524000073/brns-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001828185-24-000073
- JSON: https://secwatch.observer/filing/0001828185-24-000073.json
- Plain text: https://secwatch.observer/filing/0001828185-24-000073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.